id: sud_medication_treatment_rate_oud_to_alcohol_use_disorder
name: SUD Medication Treatment Rate â†’ Alcohol Use Disorder
from_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: SUD Medication Treatment Rate
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Access to pharmacological treatments like baclofen for AUD requires healthcare system capacity
  and provider willingness to prescribe'
- 'Step 2: Regulatory frameworks (e.g., French approval without dose limitation) enable flexible prescribing
  approaches'
- 'Step 3: Medication treatment suppresses cravings and supports abstinence or reduced drinking'
- 'Step 4: Sustained medication-assisted treatment reduces AUD prevalence and severity'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'R. de Beaurepaire and Philippe Jaury 2024. "Baclofen in the treatment of alcohol
    use disorder: tailored doses matter." https://doi.org/10.1093/alcalc/agad090'
  supporting_citations:
  - Additional citations require full-text access - abstract references multiple RCTs of baclofen
  - Additional citations require full-text access - abstract references observational studies
  - Additional citations require full-text access - abstract references meta-analyses
  doi: 10.1093/alcalc/agad090
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: The paper examines how medication treatment for AUD using baclofen, when properly implemented
  with tailored dosing, can effectively reduce alcohol use disorder. This represents a healthcare access
  mechanism where availability of evidence-based pharmacological treatments determines treatment outcomes.
spatial_variation:
  varies_by_geography: true
  variation_notes: Regulatory approval varies by country - France has approved baclofen without dose limitation
    for AUD, which may not be the case in other jurisdictions
moderators:
- name: regulatory_environment
  direction: strengthens
  strength: strong
  description: French approval without dose limitation enables tailored prescribing approaches that may
    be restricted elsewhere
structural_competency:
  equity_implications: Access to medication-assisted treatment for AUD is shaped by regulatory policies,
    healthcare system capacity, provider training, and insurance coverage - all structural factors. Geographic
    variation in approval status creates inequitable access based on where patients live. The paper's
    focus on French regulatory context highlights how policy decisions at the national level shape individual
    treatment possibilities.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.725672'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
